Antisense Technology, Part B: Applications

Other | November 1, 1999

byAbelson, John N., John N. Abelson

not yet rated|write a review
Antisense technology is the ability to manipulate gene expression within mammalian cells providing powerful experimental approaches for the study of gene function and gene regulation. For example, methods which inhibit gene expression permit studies probing the normal function of a specific product within a cell. Such methodology can be used in many disciplines such as pharmacology, oncology, genetics, cell biology, developmental biology, molecular biology, biochemistry, and neurosciences. This volume will be a truly important tool in biomedically-oriented research.
The critically acclaimed laboratory standard for more than forty years, Methods in Enzymology is one of the most highly respected publications in the field of biochemistry. Since 1955, each volume has been eagerly awaited, frequently consulted, and praised by researchers and reviewers alike. Now with more than 300 volumes (all of them still in print), the series contains much material still relevant today-truly an essential publication for researchers in all fields of life sciences.

Pricing and Purchase Info

$202.19 online
$262.47 list price (save 22%)
In stock online
Ships free on orders over $25

From the Publisher

Antisense technology is the ability to manipulate gene expression within mammalian cells providing powerful experimental approaches for the study of gene function and gene regulation. For example, methods which inhibit gene expression permit studies probing the normal function of a specific product within a cell. Such methodology can b...

Format:OtherDimensions:647 pages, 1 × 1 × 1 inPublished:November 1, 1999Publisher:Academic PressLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:0080496717

ISBN - 13:9780080496719

Customer Reviews of Antisense Technology, Part B: Applications


Extra Content

Table of Contents

Antisense Receptor Targets:
J. Garzón, I. de Antonio, and P. Sánchez-Blázquez,In vivoModulation of G-proteins and Opioid Receptor Function by Antisense Oligodeoxynucleotides.
J. Karle and M. Nielsen, Targeting Brain GABA-A Receptors with Antisense Oligonucleotides: Implications for Epilepsy.
D. Mohuezy, X. Tang, and M.I. Phillips, Delivery of Antisense DNA by Vectors for Prolonged Effectsin Vitroandin Vivo.
G.W. Pasternak and Y.-X. Pan, Antisense Mappling: Assessing the Functional Significance of Genes and Splice Variants.
E.S.J. Robinson and A.L. Hudson,In Vivoandin VitroEffects of Antisense on Þ2-Adrenoceptor Expression.
J.G. Hensler and J.M. Scalzitti, Design and Efficacy of a Seritonin2A Receptor Antisense Oligodeoxynucleotide.
M. Beinfeld and D. Vishnuvardham, The Use of Expression of Antisense mRNA for the Enzymes PC1 and PC2 in Prohormone Processing.
Antisense Neuroscience Targets:
W.C. Broaddus, S.S. Prabhu, S. Wu-Pong, G.T. Gillies, and H. Fillmore, Design and Testing of Antisense Oligonucleotide Strategies for the Central Nervous System.
N.J. Buckley, Fe.C. Abogadie, D.A. Brown, M. Dayrell, M.P. Caulfield, P. Delmas, and J.E. Haley, Use of Antisense Expression Plasmids to Attenuate G-Expression in Primary Neurons.
S. Catsicas, F. Hallböök, M. Catsicas, J.K. Staple, and G. Grenningloh, Gene Functional Analysis in the Nervous System.
S. Peng Ho, D.H.O. Britton, Y. Bao, and M.S. Scully, RNA Mapping: Selection of Potent Oligonucleotide Sequences for the Antisense Experiment.
P.S. Kalra, M.G. Dube, and S.P. Kalra, Effects of Centrality Administered Antisense Oligodeoxynucleotides on Feeding Behavior and Hormone Secretion.
J. Lai, J.C. Hunter, M.H. Ossipov, and F. Porreca, Blockade of Neuropathic Pain by Antisense Targeting of TTX-Resistant Sodium Channels in Sensory Neurons.
R. Mileusnic, Application of Antisense Approach for the Study of Cell Adhesion Molecules in the Central Nervous System.
I.D. Neumann and N. Toschi, Sequence Design and Practical Implementation of Antisense Oligonucleotides in Neuroendocrinology.
T.S. Nowak, Jr., K. Yufu, and Y. Yaida, Localization of Oligonucleotides in Brain byin situHybridization.
F. Gremo, V. Sogos, M. Curot, M. Setzu, I. Mussini, and M. Grazia Ennas, Use of Antisense Oligonucleotides in Human Neuronal and Astrocytic Cultures.
W. Sommer, M.O. Hebb, and M. Heilig, Pharmacokinetic Properties of Oligonucleotides in the Brain.
W. Tischmeyer, Antisense Oligonucleotides--Preparation andin vivoApplication to Rat Brain.
S.G. Volsen, R.C. Lambert, Y. Maulet, M.D. Waard, S. Gillard, P.J. Craig, and A. Feltz, The Application of Antisense Techniques to Characterize NEuronal Ion Channelsin vitro.
Antisense in Non-Neuronal Tissues:
M. Juhaszova and M.K. Slodzinski, Antisense Inhibition of the Na-Ca Exchanger.
E.A.L. Biessen, H. Vietsch, E.T. Rump, K. Fluiter, M.K. Bijsterbosch, and Th.J.C. van Berkel, Targeted Delivery of Antisense Oligonucleotides to Parenchymal Liver Cellin vivo.
D. Mercola, F. Bost, R. McKay, and N.M. Dean, Antisense Methods for the Discrimination of Phenotypic Properties of Closely Related Gene Products: The Jun Kinase Family.
C.L. Cioffi and B.P. Monia, Evaluation of the Biological Role of c-Jun N-terminal Kinase (NJK) using an Antisense Approach.
M.B. Ganz, The Role of Antisense in Kidney Cells.
D.L. Mattson, Use of Antisense Techniques in the Rate Renal Medulla.
T. Ochiya and M. Terada, Antisense Approaches toin vitroOrgan Culture.
E.S. Raveche, G.A. Parker, B. Peng, M. He, S. Gould-Fogerite, and C.-C. Chou,In vitroandin vivoAnti-Proliferative Effects of Antisense IL-10 Oligonucleotides.
V. Rosti, C. Lucotti, M. Cazzola, and G. Bergamaschi, Inhibition of c-ABL Expression in Hematopoietic Progenitor Cells Using Antisense Oligodeoxynucelotides.
C. Schumacher, Cellular Pharmacology of Antisense Oligodeoxynucleotides.
E. Niggli, B. Schewaller, M. Egger, and P. Lipp, Application of Antisense Oligodeoxynucelotides for the Suppression of the Na+--Ca2+Exchanger.
A. Ziegler, A.P. Simões-Wuest, and U. Zangemeister-Wittke, Optimizing the Efficacy of Antisense Oligodeoxynucleotides Targeting Inhibitors of Apoptosis.
Antisense in Therapy:
H.-T. Chung, D.-H. Sohn, B.-M. Choi, J.-C. Yoo, H.-O. Pae, and C.-D. Jun,In vivoandin vitroModulation of TGF- b 1 Gene Expression by Antisense Oligomer.
J.T. Holt, C. Rovinson-Benion, and R.A. Jensen, Analysis of Cancer Gene Functions Through Gene Inhibition with Antisense Oligonucleotides.
K.J.A. Kairemo, A.P. Jekunen, and M. Tenhunen, Dosimetry and Optimization ofin vivoTargeting with Radiolabeled Antisense Oligodeoxynucleotides (oligonucleotide radiotherapy).
S. Offensperger, W.-B. Offensperger, C. Thoma, D. Moradpour, F.V. Weizsäck, and H.E. Blum, Antisense Oligonucleotide Therapy of Hepadnavirus Infection.
E. Wickstrom and J.B. Smith, Preclinical Antisense DNA Therapy of Cancer in Mice.
M.K. Raizada, H. Wang, D. Lu, P.Y. Reaves, and M.J. Katovich, Retrovirally Medicated Delivery of Angiotensin II Type 1 Receptor (AT1R) Antisensein vitroandin vivo.